Medexus Pharmaceuticals Inc (MDP) - Total Liabilities
Based on the latest financial reports, Medexus Pharmaceuticals Inc (MDP) has total liabilities worth CA$102.77 Million CAD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Medexus Pharmaceuticals Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Medexus Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Medexus Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Medexus Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aquila European Renewables Income PLC
LSE:AERI
|
UK | €1.40 Million |
|
Intertek Group PLC
LSE:ITRK
|
UK | GBX2.34 Billion |
|
SunCar Technology Group Inc.
NASDAQ:SDA
|
USA | $185.21 Million |
|
Standard Life PLC
LSE:SDLF
|
UK | GBX308.18 Billion |
|
Fonar Corporation
NASDAQ:FONR
|
USA | $54.36 Million |
|
Osteonic Co. Ltd
KQ:226400
|
Korea | ₩32.25 Billion |
|
Shinyoung Waco
KO:005800
|
Korea | ₩39.27 Billion |
|
CammSys Corp
KQ:050110
|
Korea | ₩151.08 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Medexus Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.24 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.97 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medexus Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medexus Pharmaceuticals Inc (2012–2025)
The table below shows the annual total liabilities of Medexus Pharmaceuticals Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | CA$119.69 Million | -4.56% |
| 2024-03-31 | CA$125.41 Million | -33.19% |
| 2023-03-31 | CA$187.70 Million | +23.64% |
| 2022-03-31 | CA$151.82 Million | +16.34% |
| 2021-03-31 | CA$130.50 Million | +32.44% |
| 2020-03-31 | CA$98.53 Million | +29.54% |
| 2019-03-31 | CA$76.06 Million | +1122.95% |
| 2018-03-31 | CA$6.22 Million | -3.30% |
| 2017-03-31 | CA$6.43 Million | +32.72% |
| 2016-03-31 | CA$4.85 Million | +5.76% |
| 2015-03-31 | CA$4.58 Million | +232.95% |
| 2014-03-31 | CA$1.38 Million | +7794.83% |
| 2013-03-31 | CA$17.43K | -62.52% |
| 2012-03-31 | CA$46.51K | -- |
About Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of… Read more